GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avax Technologies Inc (OTCPK:AVXT) » Definitions » Total Liabilities

Avax Technologies (Avax Technologies) Total Liabilities : $3.45 Mil (As of Sep. 2008)


View and export this data going back to . Start your Free Trial

What is Avax Technologies Total Liabilities?

Avax Technologies's Total Liabilities for the quarter that ended in Sep. 2008 was $3.45 Mil.

Avax Technologies's quarterly Total Liabilities declined from Mar. 2008 ($3.44 Mil) to Jun. 2008 ($3.03 Mil) but then increased from Jun. 2008 ($3.03 Mil) to Sep. 2008 ($3.45 Mil).

Avax Technologies's annual Total Liabilities increased from Dec. 2005 ($1.82 Mil) to Dec. 2006 ($2.70 Mil) and increased from Dec. 2006 ($2.70 Mil) to Dec. 2007 ($3.99 Mil).


Avax Technologies Total Liabilities Historical Data

The historical data trend for Avax Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avax Technologies Total Liabilities Chart

Avax Technologies Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.88 2.43 1.82 2.70 3.99

Avax Technologies Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.94 3.99 3.44 3.03 3.45

Avax Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avax Technologies's Total Liabilities for the fiscal year that ended in Dec. 2007 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.994+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3.99

Total Liabilities=Total Assets (A: Dec. 2007 )-Total Equity (A: Dec. 2007 )
=7.377-3.383
=3.99

Avax Technologies's Total Liabilities for the quarter that ended in Sep. 2008 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.453+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3.45

Total Liabilities=Total Assets (Q: Sep. 2008 )-Total Equity (Q: Sep. 2008 )
=1.367--2.086
=3.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avax Technologies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Avax Technologies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Avax Technologies (Avax Technologies) Business Description

Traded in Other Exchanges
N/A
Address
9200 Indian Creek Parkway, Suite 200, Overland Park, KS, USA, 66210
Avax Technologies Inc is a development stage biotechnology company. The company is engaged in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. It also involved in the development and commercial readiness in the immuno-oncology arena.
Executives
Carl Spana director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017

Avax Technologies (Avax Technologies) Headlines

No Headlines